Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer

Completed · Phase 1

Conditions studied: Anaplastic Lymphoma Kinase (ALK), Non-small Cell Lung Cancer

In brief

The primary purpose of the study is to estimate the maximum tolerated dose of the combination of LDK378 and AUY922. This study will assess the safety, tolerability, pharmacokinetics and preliminary evidence of anti-tumor activity of the combination of LDK378 and AUY922 in ALK-rearranged non-small cell lung cancer.

Key facts

Study ID

NCT01772797

Run by

Novartis Pharmaceuticals

People needed

22

Starts

2013-06-01

Expected to finish

2016-01-01

Last updated by the study team

2020-12-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• locally advanced or metastatic NSCLC that has progressed during or following therapy with an ALK inhibitor
• tumor must carry an ALK rearrangement in 15% or more of tumor cells as measured by FISH
• disease that can be evaluated by RECIST v1.1 and measurable disease

You may not qualify if…

• central nervous system (CNS) metastases that are symptomatic or require increasing steroids or CNS-directed therapy to control CNS disease
• history of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis
• clinically significant cardiac dysfunction
• inadequate end organ function as defined by specified laboratory values
• use of medications known to be strong inhibitors or inducters of CYP3A4/5 that cannot be discontinued at least 1 week prior to start of treatment
• use of medications that are mainly metabolized by CYP3A4/5 or CYP2C9 that cannot be discontinued at least 1 week prior to start of treatment
• clinically significant, uncontrolled impaired gastrointestinal function or GI disease
• prior treatment with a HSP90 inhibitor
• radiotherapy to lung within 4 weeks prior to the first dose of study treatment or patients who have not recovered from radiotherapy-related toxicities
• pregnant or nursing women
• history of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease.

Where it is running

• University of Colorado Dept. of Anschutz Cancer (3) — Aurora, Colorado, United States
• Massachusetts General Hospital Mass General — Boston, Massachusetts, United States
• Fox Chase Cancer Center Fox Chase Cancer (2) — Philadelphia, Pennsylvania, United States
• University of Utah / Huntsman Cancer Institute Huntsman — Salt Lake City, Utah, United States
• Novartis Investigative Site — Melbourne, Victoria, Australia
• Novartis Investigative Site — Milan, MI, Italy
• Novartis Investigative Site — Singapore, Singapore
• Novartis Investigative Site — Barcelona, Catalonia, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.